Chimeric TK-NOG mice: A predictive model for cholestatic human liver toxicity

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 2, 2015, Pages 274-280

  Xu, Dan ^a   Wu, Manhong ^a   Nishimura, Sachiko ^b   Nishimura, Toshihiko ^a,b,c   Michie, Sara A ^a   Zheng, Ming ^a   Yang, Zicheng ^d   Yates, Alexander John ^d   Day, Jeffrey S ^e   Hillgren, Kathleen M ^e   Takeda, Saori Takedai ^f   Guan, Yuan ^a   Guo, Yingying ^e   Peltz, Gary ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for the Advancement of Health and Bioscience   (United States)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^d Bruker CAM and LSC7   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f In Vivo Sciences International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BOSENTAN; CEFAZOLIN; CEFMETAZOLE; GAMMA GLUTAMYLTRANSFERASE; PROBENECID; RIFAMPICIN; THYMIDINE KINASE; GANCICLOVIR; SULFONAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CHIMERA; CHOLESTASIS; CHOLESTATIC HEPATITIS; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; LIVER METABOLISM; LIVER PERFUSION; LIVER TOXICITY; MOUSE; NONHUMAN; PREDICTIVE VALUE; TK NOG GENE; TOXIC HEPATITIS; TOXICOKINETICS; TRANSGENE; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG SCREENING; GENETICS; HUMAN; LIVER CELL; METABOLIC CLEARANCE RATE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; TRANSPLANTATION;

ANIMALS; CEFMETAZOLE; CHOLESTASIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; GANCICLOVIR; HEPATOCYTES; HUMANS; METABOLIC CLEARANCE RATE; MICE, TRANSGENIC; SPECIES SPECIFICITY; SULFONAMIDES; THYMIDINE KINASE; TISSUE DISTRIBUTION; TRANSGENES;

EID: 84919771983     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.220798     Document Type: Article

References (28)

1. Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243-256.
2. Benjamini Y and Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B 57:289-300.
3. Dueland S, Reichen J, Everson GT, and Davis RA (1991) Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem J 280:373-377.
4. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231.
5. Fouassier L, Kinnman N, Lefèvre G, Lasnier E, Rey C, Poupon R, Elferink RP, and Housset C (2002) Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 37:184-191.
6. Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, NakamuraM, et al. (2011) The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405: 405-410.
7. Hu Y, Wu M, Nishimura T, Zheng M, and Peltz G (2013) Human pharmacogenetic analysis in chimeric mice with 'humanized livers.' Pharmacogenet Genomics 23:78-83.
8. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, and Hoeper MM (2007) Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30:338-344.
9. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, and Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412.
10. Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, and Evans DC (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 22:280-293.
11. Luo G, Johnson S, Hsueh MM, Zheng J, Cai H, Xin B, Chong S, He K, and Harper TW (2010) In silico prediction of biliary excretion of drugs in rats based on physicochemical properties. Drug Metab Dispos 38:422-430.
12. Manning FJ and Swartz MN (1995) Review of the Fialuridine (FIAU) Clinical Trials, National Academy Press, Washington, D.C.
13. Mano Y, Usui T, and Kamimura H (2007) Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 28:13-18.
14. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, et al. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333:1099-1105.
15. Naito T, Kuroki S, Chijiiwa K, and Tanaka M (1996) Bile acid synthesis and biliary hydrophobicity during obstructive jaundice in rats. J Surg Res 65:70-76.
16. Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin C, Angus P, et al. (2013) Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 344:388-396.
17. Okumura H, Katoh M, Sawada T, Nakajima M, Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, and Yokoi T (2007) Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533-538.
18. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, et al.; U.S. Acute Liver Failure Study Group (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947-954.
19. Peltz G (2013) Can 'humanized' mice improve drug development in the 21st century? Trends Pharmacol Sci 34:255-260.
20. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903.
21. Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137-174.
22. Takita M, Ikawa S, and Ogura Y (1988) Effect of bile duct ligation on bile acid and cholesterol metabolism in rats. J Biochem 103:778-786.
23. Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, and Wright P (2009) A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 22:1653-1662.
24. Watkins PB and Seeff LB (2006) Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 43:618-631.
25. Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, et al. (2008) PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol 48:849-889.
26. Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo Y-Y, Masek M, Michie SA, Glenn J, and Peltz G (2014) Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med 11:e1001628.
27. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133.
28. Zhang Y, Hong JY, Rockwell CE, Copple BL, Jaeschke H, and Klaassen CD (2012) Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int 32:58-69